Nordic Nanovector is focusing on the development and commercialization of novel targeted therapeutics for haematological cancers.
The Company’s lead clinical-stage product opportunity is Betalutin™, the first in a new class of Antibody-Radionuclide-Conjugates (ARCs), designed to improve upon and complement current options for the treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities.
Nordic Nanovector was established in 2009, leveraging expertise in targeted cancer therapy from the Norwegian Radium Hospital, and has its main office and laboratories in Oslo, Norway.
Events and Highlights
17-20 June 2015
13th International Conference on Malignant Lymphoma (ICML)
Betalutin™ data and analysis will be presented in a poster on 18-19 June 2015